• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of gutGutVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Gut. May 2004; 53(Suppl 4): iv1–iv24.
PMCID: PMC1867782

Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs

Full Text

The Full Text of this article is available as a PDF (353K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Kay L, Jørgensen T, Jensen KH. Epidemiology of abdominal symptoms in a random population: prevalence, incidence, and natural history. Eur J Epidemiol. 1994 Oct;10(5):559–566. [PubMed]
  • Talley NJ, Meineche-Schmidt V, Paré P, Duckworth M, Räisänen P, Pap A, Kordecki H, Schmid V. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther. 1998 Nov;12(11):1055–1065. [PubMed]
  • Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999 Mar 18;340(11):825–831. [PubMed]
  • An evidence-based appraisal of reflux disease management--the Genval Workshop Report. Gut. 1999 Apr;44 (Suppl 2):S1–16. [PMC free article] [PubMed]
  • Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999 Aug;45(2):172–180. [PMC free article] [PubMed]
  • Klauser AG, Schindlbeck NE, Müller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet. 1990 Jan 27;335(8683):205–208. [PubMed]
  • Schindlbeck NE, Klauser AG, Voderholzer WA, Müller-Lissner SA. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med. 1995 Sep 11;155(16):1808–1812. [PubMed]
  • Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Festen HP, Jansen EH, Tuynman HA, Schrijver M, Dieleman LA, Meuwissen SG. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol. 1997 Nov;92(11):1997–2000. [PubMed]
  • Johnsson F, Weywadt L, Solhaug JH, Hernqvist H, Bengtsson L. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol. 1998 Jan;33(1):15–20. [PubMed]
  • Fass R, Ofman JJ, Gralnek IM, Johnson C, Camargo E, Sampliner RE, Fennerty MB. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med. 1999 Oct 11;159(18):2161–2168. [PubMed]
  • Moayyedi P, Forman D, Braunholtz D, Feltbower R, Crocombe W, Liptrott M, Axon A. The proportion of upper gastrointestinal symptoms in the community associated with Helicobacter pylori, lifestyle factors, and nonsteroidal anti-inflammatory drugs. Leeds HELP Study Group. Am J Gastroenterol. 2000 Jun;95(6):1448–1455. [PubMed]
  • Castell Donald O, Kahrilas Peter J, Richter Joel E, Vakil Nimish B, Johnson David A, Zuckerman Seth, Skammer Wendy, Levine Jeffrey G. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002 Mar;97(3):575–583. [PubMed]
  • Lassen AT, Pedersen FM, Bytzer P, Schaffalitzky de Muckadell OB. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial. Lancet. 2000 Aug 5;356(9228):455–460. [PubMed]
  • Farup PG, Hovde O, Torp R, Wetterhus S. Patients with functional dyspepsia responding to omeprazole have a characteristic gastro-oesophageal reflux pattern. Scand J Gastroenterol. 1999 Jun;34(6):575–579. [PubMed]
  • Earlam RJ. Production of epigastric pain in duodenal ulcer by lower oesophageal acid perfusion. Br Med J. 1970 Dec 19;4(5737):714–716. [PMC free article] [PubMed]
  • Shaw MJ, Talley NJ, Beebe TJ, Rockwood T, Carlsson R, Adlis S, Fendrick AM, Jones R, Dent J, Bytzer P. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol. 2001 Jan;96(1):52–57. [PubMed]
  • Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, Haug K, de Groot G, van Oudvorst A, Dalväg A, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol. 1998 Feb;10(2):119–124. [PubMed]
  • Johnsen R, Bernersen B, Straume B, Førde OH, Bostad L, Burhol PG. Prevalences of endoscopic and histological findings in subjects with and without dyspepsia. BMJ. 1991 Mar 30;302(6779):749–752. [PMC free article] [PubMed]
  • Johnsson F, Roth Y, Damgaard Pedersen NE, Joelsson B. Cimetidine improves GERD symptoms in patients selected by a validated GERD questionnaire. Aliment Pharmacol Ther. 1993 Feb;7(1):81–86. [PubMed]
  • Carlsson R, Dent J, Bolling-Sternevald E, Johnsson F, Junghard O, Lauritsen K, Riley S, Lundell L. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol. 1998 Oct;33(10):1023–1029. [PubMed]
  • Moayyedi P, Axon AT. The usefulness of the likelihood ratio in the diagnosis of dyspepsia and gastroesophageal reflux disease. Am J Gastroenterol. 1999 Nov;94(11):3122–3125. [PubMed]
  • Locke GR, Talley NJ, Weaver AL, Zinsmeister AR. A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc. 1994 Jun;69(6):539–547. [PubMed]
  • Hansen JM, Bytzer P, Schaffalitzky De Muckadell OB. Management of dyspeptic patients in primary care. Value of the unaided clinical diagnosis and of dyspepsia subgrouping. Scand J Gastroenterol. 1998 Aug;33(8):799–805. [PubMed]
  • Johnsson F, Joelsson B, Gudmundsson K, Greiff L. Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol. 1987 Aug;22(6):714–718. [PubMed]
  • Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JF., Jr The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA. 1995 Aug 9;274(6):474–477. [PubMed]
  • Kahrilas PJ, Quigley EM. Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology. 1996 Jun;110(6):1982–1996. [PubMed]
  • Ho KY, Ng WL, Kang JY, Yeoh KG. Gastroesophageal reflux disease is a common cause of noncardiac chest pain in a country with a low prevalence of reflux esophagitis. Dig Dis Sci. 1998 Sep;43(9):1991–1997. [PubMed]
  • Fass R, Fennerty MB, Ofman JJ, Gralnek IM, Johnson C, Camargo E, Sampliner RE. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology. 1998 Jul;115(1):42–49. [PubMed]
  • Achem SR, Kolts BE, MacMath T, Richter J, Mohr D, Burton L, Castell DO. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci. 1997 Oct;42(10):2138–2145. [PubMed]
  • Chambers J, Cooke R, Anggiansah A, Owen W. Effect of omeprazole in patients with chest pain and normal coronary anatomy: initial experience. Int J Cardiol. 1998 Jun 1;65(1):51–55. [PubMed]
  • So JB, Zeitels SM, Rattner DW. Outcomes of atypical symptoms attributed to gastroesophageal reflux treated by laparoscopic fundoplication. Surgery. 1998 Jul;124(1):28–32. [PubMed]
  • Rothwell JF, Feehan E, Reid I, Walsh TN, Hennessy TP. Delay in treatment for oesophageal cancer. Br J Surg. 1997 May;84(5):690–693. [PubMed]
  • Ruth M, Månsson I, Sandberg N. The prevalence of symptoms suggestive of esophageal disorders. Scand J Gastroenterol. 1991 Jan;26(1):73–81. [PubMed]
  • Lindgren S, Janzon L. Prevalence of swallowing complaints and clinical findings among 50-79-year-old men and women in an urban population. Dysphagia. 1991;6(4):187–192. [PubMed]
  • Isolauri J, Laippala P. Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population. Ann Med. 1995 Feb;27(1):67–70. [PubMed]
  • Wallace MB, Durkalski VL, Vaughan J, Palesch YY, Libby ED, Jowell PS, Nickl NJ, Schutz SM, Leung JW, Cotton PB. Age and alarm symptoms do not predict endoscopic findings among patients with dyspepsia: a multicentre database study. Gut. 2001 Jul;49(1):29–34. [PMC free article] [PubMed]
  • Adang RP, Vismans JF, Talmon JL, Hasman A, Ambergen AW, Stockbrügger RW. Appropriateness of indications for diagnostic upper gastrointestinal endoscopy: association with relevant endoscopic disease. Gastrointest Endosc. 1995 Nov;42(5):390–397. [PubMed]
  • Numans ME, van der Graaf Y, de Wit NJ, de Melker RA. How useful is selection based on alarm symptoms in requesting gastroscopy? An evaluation of diagnostic determinants for gastro-oesophageal malignancy. Scand J Gastroenterol. 2001 Apr;36(4):437–443. [PubMed]
  • Madsen LG, Bytzer P. The value of alarm features in identifying organic causes of dyspepsia. Can J Gastroenterol. 2000 Sep;14(8):713–720. [PubMed]
  • Csendes A, Smok G, Burdiles P, Quesada F, Huertas C, Rojas J, Korn O. Prevalence of Barrett's esophagus by endoscopy and histologic studies: a prospective evaluation of 306 control subjects and 376 patients with symptoms of gastroesophageal reflux. Dis Esophagus. 2000;13(1):5–11. [PubMed]
  • Robinson M, Earnest D, Rodriguez-Stanley S, Greenwood-Van Meerveld B, Jaffe P, Silver MT, Kleoudis CS, Wilson LE, Murdock RH. Heartburn requiring frequent antacid use may indicate significant illness. Arch Intern Med. 1998 Nov 23;158(21):2373–2376. [PubMed]
  • Winters C, Jr, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker JF, 3rd, Johnson DA, Cruess DF, Cotelingam JD, Gurney MS, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology. 1987 Jan;92(1):118–124. [PubMed]
  • Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol. 1997 Aug;92(8):1293–1297. [PubMed]
  • Romero Yvonne, Cameron Alan J, Schaid Daniel J, McDonnell Shannon K, Burgart Lawrence J, Hardtke Cyndy L, Murray Joseph A, Locke G Richard., 3rd Barrett's esophagus: prevalence in symptomatic relatives. Am J Gastroenterol. 2002 May;97(5):1127–1132. [PubMed]
  • Farrow DC, Vaughan TL, Sweeney C, Gammon MD, Chow WH, Risch HA, Stanford JL, Hansten PD, Mayne ST, Schoenberg JB, et al. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control. 2000 Mar;11(3):231–238. [PubMed]
  • Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology. 1992 Oct;103(4):1241–1245. [PubMed]
  • Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol. 1999 Jan;94(1):86–91. [PubMed]
  • Blot WJ, Devesa SS, Kneller RW, Fraumeni JF., Jr Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991 Mar 13;265(10):1287–1289. [PubMed]
  • Conio M, Cameron AJ, Romero Y, Branch CD, Schleck CD, Burgart LJ, Zinsmeister AR, Melton LJ, 3rd, Locke GR., 3rd Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut. 2001 Mar;48(3):304–309. [PMC free article] [PubMed]
  • Powell Jean, McConkey Chris C, Gillison E Walford, Spychal Robert T. Continuing rising trend in oesophageal adenocarcinoma. Int J Cancer. 2002 Dec 1;102(4):422–427. [PubMed]
  • Powell J, McConkey CC. The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev. 1992 Apr;1(3):265–269. [PubMed]
  • Vizcaino A Paloma, Moreno Victor, Lambert Rene, Parkin D Maxwell. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer. 2002 Jun 20;99(6):860–868. [PubMed]
  • Wijnhoven Bas P L, Louwman Marieke W J, Tilanus Hugo W, Coebergh Jan-Willem W. Increased incidence of adenocarcinomas at the gastro-oesophageal junction in Dutch males since the 1990s. Eur J Gastroenterol Hepatol. 2002 Feb;14(2):115–122. [PubMed]
  • Blot WJ, Devesa SS, Fraumeni JF., Jr Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA. 1993 Sep 15;270(11):1320–1320. [PubMed]
  • Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97–102. [PubMed]
  • Bani-Hani K, Sue-Ling H, Johnston D, Axon AT, Martin IG. Barrett's oesophagus: results from a 13-year surveillance programme. Eur J Gastroenterol Hepatol. 2000 Jun;12(6):649–654. [PubMed]
  • Forman David. Counting cancers at the junction - a problem of routine statistics. Eur J Gastroenterol Hepatol. 2002 Feb;14(2):99–101. [PubMed]
  • Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology. 2000 Aug;119(2):333–338. [PubMed]
  • Gerson Lauren B, Shetler Katerina, Triadafilopoulos George. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology. 2002 Aug;123(2):461–467. [PubMed]
  • Lind T, Havelund T, Carlsson R, Anker-Hansen O, Glise H, Hernqvist H, Junghard O, Lauritsen K, Lundell L, Pedersen SA, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997 Oct;32(10):974–979. [PubMed]
  • Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol. 1997 Oct;32(10):965–973. [PubMed]
  • Bate CM, Griffin SM, Keeling PW, Axon AT, Dronfield MW, Chapman RW, O'Donoghue D, Calam J, Crowe J, Mountfords RA, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther. 1996 Aug;10(4):547–555. [PubMed]
  • Frank L, Kleinman L, Ganoczy D, McQuaid K, Sloan S, Eggleston A, Tougas G, Farup C. Upper gastrointestinal symptoms in North America: prevalence and relationship to healthcare utilization and quality of life. Dig Dis Sci. 2000 Apr;45(4):809–818. [PubMed]
  • Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, D'Amico D, Hamelin B, Joelsson B. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther. 2000 Oct;14(10):1249–1258. [PubMed]
  • Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, Marino V, Hamelin B, Levine JG. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001 Mar;96(3):656–665. [PubMed]
  • Hyland ME, Kenyon CA, Allen R, Howarth P. Diary keeping in asthma: comparison of written and electronic methods. BMJ. 1993 Feb 20;306(6876):487–489. [PMC free article] [PubMed]
  • Stone Arthur A, Shiffman Saul, Schwartz Joseph E, Broderick Joan E, Hufford Michael R. Patient non-compliance with paper diaries. BMJ. 2002 May 18;324(7347):1193–1194. [PMC free article] [PubMed]
  • Guyatt GH, Townsend M, Berman LB, Keller JL. A comparison of Likert and visual analogue scales for measuring change in function. J Chronic Dis. 1987;40(12):1129–1133. [PubMed]
  • Ferraz MB, Quaresma MR, Aquino LR, Atra E, Tugwell P, Goldsmith CH. Reliability of pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis. J Rheumatol. 1990 Aug;17(8):1022–1024. [PubMed]
  • Huskisson EC. Measurement of pain. Lancet. 1974 Nov 9;2(7889):1127–1131. [PubMed]
  • Talley NJ, Fullerton S, Junghard O, Wiklund I. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol. 2001 Jul;96(7):1998–2004. [PubMed]
  • Veldhuyzen van Zanten SJ, Tytgat KM, Pollak PT, Goldie J, Goodacre RL, Riddell RH, Hunt RH. Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia and Helicobacter pylori associated gastritis? J Clin Epidemiol. 1993 Mar;46(3):273–279. [PubMed]
  • Armstrong D, Paré P, Pericak D, Pyzyk M. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol. 2001 Oct;96(10):2849–2857. [PubMed]
  • Eisendrath P, Tack J, Devière J. Diagnosis of gastroesophageal reflux disease in general practice: a Belgian national survey. Endoscopy. 2002 Dec;34(12):998–1003. [PubMed]
  • Allgood PC, Bachmann M. Medical or surgical treatment for chronic gastrooesophageal reflux? A systematic review of published evidence of effectiveness. Eur J Surg. 2000 Sep;166(9):713–721. [PubMed]
  • Sandbu R, Khamis H, Gustavsson S, Haglund U. Long-term results of antireflux surgery indicate the need for a randomized clinical trial. Br J Surg. 2002 Feb;89(2):225–230. [PubMed]
  • Lind T, Havelund T, Lundell L, Glise H, Lauritsen K, Pedersen SA, Anker-Hansen O, Stubberöd A, Eriksson G, Carlsson R, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial. Aliment Pharmacol Ther. 1999 Jul;13(7):907–914. [PubMed]
  • Talley Nicholas J, Venables Thomas L, Green Jonathan R B, Armstrong David, O'Kane Kevin P J, Giaffer Mustafa, Bardhan Karna D, Carlsson Rolf G S, Chen Samuel, Hasselgren Göran S. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol. 2002 Aug;14(8):857–863. [PubMed]
  • Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, Raufman JP, Sampliner R, Schnell T, Sontag S, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA. 2001 May 9;285(18):2331–2338. [PubMed]
  • Lord Reginald V N, Kaminski Anna, Oberg Stefan, Bowrey David J, Hagen Jeffrey A, DeMeester Steven R, Sillin Lelan F, Peters Jeffrey H, Crookes Peter F, DeMeester Tom R. Absence of gastroesophageal reflux disease in a majority of patients taking acid suppression medications after Nissen fundoplication. J Gastrointest Surg. 2002 Jan-Feb;6(1):3–10. [PubMed]
  • Carlsson R, Galmiche JP, Dent J, Lundell L, Frison L. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther. 1997 Jun;11(3):473–482. [PubMed]
  • Fass R, Ofman JJ, Sampliner RE, Camargo L, Wendel C, Fennerty MB. The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment Pharmacol Ther. 2000 Apr;14(4):389–396. [PubMed]
  • Fass R. Empirical trials in treatment of gastroesophageal reflux disease. Dig Dis. 2000;18(1):20–26. [PubMed]
  • Fink P. Surgery and medical treatment in persistent somatizing patients. J Psychosom Res. 1992 Jul;36(5):439–447. [PubMed]
  • Harding SM, Richter JE, Guzzo MR, Schan CA, Alexander RW, Bradley LA. Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am J Med. 1996 Apr;100(4):395–405. [PubMed]
  • Wong RK, Hanson DG, Waring PJ, Shaw G. ENT manifestations of gastroesophageal reflux. Am J Gastroenterol. 2000 Aug;95(8 Suppl):S15–S22. [PubMed]
  • Harding SM, Sontag SJ. Asthma and gastroesophageal reflux. Am J Gastroenterol. 2000 Aug;95(8 Suppl):S23–S32. [PubMed]
  • Irwin RS, Richter JE. Gastroesophageal reflux and chronic cough. Am J Gastroenterol. 2000 Aug;95(8 Suppl):S9–14. [PubMed]
  • Belafsky PC, Postma GN, Koufman JA. Laryngopharyngeal reflux symptoms improve before changes in physical findings. Laryngoscope. 2001 Jun;111(6):979–981. [PubMed]
  • Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997 Jun;112(6):1798–1810. [PubMed]
  • Branski Ryan C, Bhattacharyya Neil, Shapiro Jo. The reliability of the assessment of endoscopic laryngeal findings associated with laryngopharyngeal reflux disease. Laryngoscope. 2002 Jun;112(6):1019–1024. [PubMed]
  • Ours TM, Kavuru MS, Schilz RJ, Richter JE. A prospective evaluation of esophageal testing and a double-blind, randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough. Am J Gastroenterol. 1999 Nov;94(11):3131–3138. [PubMed]
  • Rothman M, Farup C, Stewart W, Helbers L, Zeldis J. Symptoms associated with gastroesophageal reflux disease: development of a questionnaire for use in clinical trials. Dig Dis Sci. 2001 Jul;46(7):1540–1549. [PubMed]
  • Mathias SD, Colwell HH, Miller DP, Pasta DJ, Henning JM, Ofman JJ. Health-Related quality-of-life and quality-days incrementally gained in symptomatic nonerosive GERD patients treated with lansoprazole or ranitidine. Dig Dis Sci. 2001 Nov;46(11):2416–2423. [PubMed]
  • Wiklund I, Dimenäs E, Wahl M. Factors of importance when evaluating quality of life in clinical trials. Control Clin Trials. 1990 Jun;11(3):169–179. [PubMed]
  • Farup C, Kleinman L, Sloan S, Ganoczy D, Chee E, Lee C, Revicki D. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med. 2001 Jan 8;161(1):45–52. [PubMed]
  • Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol. 1993 Dec;46(12):1417–1432. [PubMed]
  • Stacey JH, Miocevich ML, Sacks GE. The effect of ranitidine (as effervescent tablets) on the quality of life of GORD patients. Br J Clin Pract. 1996 Jun;50(4):190–196. [PubMed]
  • Koch T. Life quality vs the 'quality of life': assumptions underlying prospective quality of life instruments in health care planning. Soc Sci Med. 2000 Aug;51(3):419–427. [PubMed]
  • O'Connor AM, Rostom A, Fiset V, Tetroe J, Entwistle V, Llewellyn-Thomas H, Holmes-Rovner M, Barry M, Jones J. Decision aids for patients facing health treatment or screening decisions: systematic review. BMJ. 1999 Sep 18;319(7212):731–734. [PMC free article] [PubMed]
  • Havelund T, Lind T, Wiklund I, Glise H, Hernqvist H, Lauritsen K, Lundell L, Pedersen SA, Carlsson R, Junghard O, et al. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol. 1999 Jul;94(7):1782–1789. [PubMed]
  • Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med. 1998 Mar;104(3):252–258. [PubMed]
  • Wilhelmsen I, Hatlebakk JG, Olafsson S, Berstad A. On demand therapy of reflux oesophagitis--a prospective study of symptoms, patient satisfaction and quality of life. Aliment Pharmacol Ther. 1999 Aug;13(8):1035–1040. [PubMed]
  • Wiersma D, van Busschbach J. Are needs and satisfaction of care associated with quality of life? An epidemiological survey among the severely mentally ill in the Netherlands. Eur Arch Psychiatry Clin Neurosci. 2001 Oct;251(5):239–246. [PubMed]
  • Redekop W Ken, Koopmanschap Marc A, Stolk Ronald P, Rutten Guy E H M, Wolffenbuttel Bruce H R, Niessen Louis W. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care. 2002 Mar;25(3):458–463. [PubMed]
  • Elf M, Wikblad K. Satisfaction with information and quality of life in patients undergoing chemotherapy for cancer. The role of individual differences in information preference. Cancer Nurs. 2001 Oct;24(5):351–356. [PubMed]
  • Vakil Nimish, Shaw Michael, Kirby Russell. Clinical effectiveness of laparoscopic fundoplication in a U.S. community. Am J Med. 2003 Jan;114(1):1–5. [PubMed]
  • Lydeard S, Jones R. Factors affecting the decision to consult with dyspepsia: comparison of consulters and non-consulters. J R Coll Gen Pract. 1989 Dec;39(329):495–498. [PMC free article] [PubMed]
  • Hungin AP, Thomas PR, Bramble MG, Corbett WA, Idle N, Contractor BR, Berridge DC, Cann G. What happens to patients following open access gastroscopy? An outcome study from general practice. Br J Gen Pract. 1994 Nov;44(388):519–521. [PMC free article] [PubMed]
  • Delaney BC. Why do dyspeptic patients over the age of 50 consult their general practitioner? A qualitative investigation of health beliefs relating to dyspepsia. Br J Gen Pract. 1998 Aug;48(433):1481–1485. [PMC free article] [PubMed]
  • Westbrook JI, McIntosh J, Talley NJ. Factors associated with consulting medical or non-medical practitioners for dyspepsia: an australian population-based study. Aliment Pharmacol Ther. 2000 Dec;14(12):1581–1588. [PubMed]
  • Kleinman Leah, McIntosh Emma, Ryan Mandy, Schmier Jordana, Crawley Joseph, Locke G Richard, 3rd, De Lissovoy Gregory. Willingness to pay for complete symptom relief of gastroesophageal reflux disease. Arch Intern Med. 2002 Jun 24;162(12):1361–1366. [PubMed]
  • Mangione-Smith R, McGlynn EA, Elliott MN, McDonald L, Franz CE, Kravitz RL. Parent expectations for antibiotics, physician-parent communication, and satisfaction. Arch Pediatr Adolesc Med. 2001 Jul;155(7):800–806. [PubMed]
  • Bate CM, Green JR, Axon AT, Murray FE, Tildesley G, Emmas CE, Taylor MD. Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther. 1997 Aug;11(4):755–763. [PubMed]
  • Condra LJ, Morreale AP, Stolley SN, Marcus D. Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy. Am J Manag Care. 1999 May;5(5):631–638. [PubMed]

Figures and Tables

Figure 1
Most patients accept up to one day with mild heartburn per week during treatment. Few accept more frequent heartburn or moderate/severe heartburn.10
Figure 2
Patients with severe heartburn are likely to have more frequent heartburn than those with mild heartburn (AstraZeneca, data on file).

Articles from Gut are provided here courtesy of BMJ Group


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...